These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
226 related articles for article (PubMed ID: 22021082)
1. Inclusion of a portion of the native SNCA 3'UTR reduces toxicity of human S129A SNCA on striatal-projecting dopamine neurons in rat substantia nigra. Khodr CE; Pedapati J; Han Y; Bohn MC Dev Neurobiol; 2012 Jun; 72(6):906-17. PubMed ID: 22021082 [TBL] [Abstract][Full Text] [Related]
2. Targeting alpha-synuclein with a microRNA-embedded silencing vector in the rat substantia nigra: positive and negative effects. Khodr CE; Becerra A; Han Y; Bohn MC Brain Res; 2014 Mar; 1550():47-60. PubMed ID: 24463035 [TBL] [Abstract][Full Text] [Related]
3. An α-synuclein AAV gene silencing vector ameliorates a behavioral deficit in a rat model of Parkinson's disease, but displays toxicity in dopamine neurons. Khodr CE; Sapru MK; Pedapati J; Han Y; West NC; Kells AP; Bankiewicz KS; Bohn MC Brain Res; 2011 Jun; 1395():94-107. PubMed ID: 21565333 [TBL] [Abstract][Full Text] [Related]
4. Heat shock protein 70 reduces α-synuclein-induced predegenerative neuronal dystrophy in the α-synuclein viral gene transfer rat model of Parkinson's disease. Moloney TC; Hyland R; O'Toole D; Paucard A; Kirik D; O'Doherty A; Gorman AM; Dowd E CNS Neurosci Ther; 2014 Jan; 20(1):50-8. PubMed ID: 24279716 [TBL] [Abstract][Full Text] [Related]
5. AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease. Ip CW; Klaus LC; Karikari AA; Visanji NP; Brotchie JM; Lang AE; Volkmann J; Koprich JB Acta Neuropathol Commun; 2017 Feb; 5(1):11. PubMed ID: 28143577 [TBL] [Abstract][Full Text] [Related]
6. Human α-synuclein overexpression upregulates SKOR1 in a rat model of simulated nigrostriatal ageing. Morales-Prieto N; Bevans R; O'Mahony A; Barron A; Giles Doran C; McCarthy E; Concannon RM; Goulding SR; McCarthy CM; Collins LM; Sullivan AM; O'Keeffe GW Aging Cell; 2024 Jun; 23(6):e14155. PubMed ID: 38529808 [TBL] [Abstract][Full Text] [Related]
8. Ser129D mutant alpha-synuclein induces earlier motor dysfunction while S129A results in distinctive pathology in a rat model of Parkinson's disease. Febbraro F; Sahin G; Farran A; Soares S; Jensen PH; Kirik D; Romero-Ramos M Neurobiol Dis; 2013 Aug; 56():47-58. PubMed ID: 23567651 [TBL] [Abstract][Full Text] [Related]
9. A microRNA embedded AAV α-synuclein gene silencing vector for dopaminergic neurons. Han Y; Khodr CE; Sapru MK; Pedapati J; Bohn MC Brain Res; 2011 Apr; 1386():15-24. PubMed ID: 21338582 [TBL] [Abstract][Full Text] [Related]
10. Aldehyde dehydrogenase 1 defines and protects a nigrostriatal dopaminergic neuron subpopulation. Liu G; Yu J; Ding J; Xie C; Sun L; Rudenko I; Zheng W; Sastry N; Luo J; Rudow G; Troncoso JC; Cai H J Clin Invest; 2014 Jul; 124(7):3032-46. PubMed ID: 24865427 [TBL] [Abstract][Full Text] [Related]
11. T cell infiltration and upregulation of MHCII in microglia leads to accelerated neuronal loss in an α-synuclein rat model of Parkinson's disease. Subbarayan MS; Hudson C; Moss LD; Nash KR; Bickford PC J Neuroinflammation; 2020 Aug; 17(1):242. PubMed ID: 32799878 [TBL] [Abstract][Full Text] [Related]
12. Delivery of a GDNF gene into the substantia nigra after a progressive 6-OHDA lesion maintains functional nigrostriatal connections. Kozlowski DA; Connor B; Tillerson JL; Schallert T; Bohn MC Exp Neurol; 2000 Nov; 166(1):1-15. PubMed ID: 11031079 [TBL] [Abstract][Full Text] [Related]
13. GM1 Ganglioside Modifies α-Synuclein Toxicity and is Neuroprotective in a Rat α-Synuclein Model of Parkinson's Disease. Schneider JS; Aras R; Williams CK; Koprich JB; Brotchie JM; Singh V Sci Rep; 2019 Jun; 9(1):8362. PubMed ID: 31182727 [TBL] [Abstract][Full Text] [Related]
14. Alpha-synuclein S129 phosphorylation mutants do not alter nigrostriatal toxicity in a rat model of Parkinson disease. McFarland NR; Fan Z; Xu K; Schwarzschild MA; Feany MB; Hyman BT; McLean PJ J Neuropathol Exp Neurol; 2009 May; 68(5):515-24. PubMed ID: 19525899 [TBL] [Abstract][Full Text] [Related]
15. Comparison of the behavioural and histological characteristics of the 6-OHDA and α-synuclein rat models of Parkinson's disease. Decressac M; Mattsson B; Björklund A Exp Neurol; 2012 May; 235(1):306-15. PubMed ID: 22394547 [TBL] [Abstract][Full Text] [Related]
16. Progressive neurodegeneration or endogenous compensation in an animal model of Parkinson's disease produced by decreasing doses of alpha-synuclein. Koprich JB; Johnston TH; Huot P; Reyes MG; Espinosa M; Brotchie JM PLoS One; 2011 Mar; 6(3):e17698. PubMed ID: 21408191 [TBL] [Abstract][Full Text] [Related]
17. Response of the GABAergic and dopaminergic mesostriatal projections to the lesion of the contralateral dopaminergic mesostriatal pathway in the rat. González-Hernández T; Barroso-Chinea P; Rodríguez M Mov Disord; 2004 Sep; 19(9):1029-1042. PubMed ID: 15372592 [TBL] [Abstract][Full Text] [Related]
18. Minocycline inhibition of microglial rescues nigrostriatal dopaminergic neurodegeneration caused by mutant alpha-synuclein overexpression. Wang Y; Wang Q; Yu R; Zhang Q; Zhang Z; Li H; Ren C; Yang R; Niu H Aging (Albany NY); 2020 Jul; 12(14):14232-14243. PubMed ID: 32706757 [TBL] [Abstract][Full Text] [Related]
19. Bacterial artificial chromosome transgenic mice expressing a truncated mutant parkin exhibit age-dependent hypokinetic motor deficits, dopaminergic neuron degeneration, and accumulation of proteinase K-resistant alpha-synuclein. Lu XH; Fleming SM; Meurers B; Ackerson LC; Mortazavi F; Lo V; Hernandez D; Sulzer D; Jackson GR; Maidment NT; Chesselet MF; Yang XW J Neurosci; 2009 Feb; 29(7):1962-76. PubMed ID: 19228951 [TBL] [Abstract][Full Text] [Related]
20. Intracerebral Administration of a Ligand-ASO Conjugate Selectively Reduces α-Synuclein Accumulation in Monoamine Neurons of Double Mutant Human A30P*A53T*α-Synuclein Transgenic Mice. Pavia-Collado R; Cóppola-Segovia V; Miquel-Rio L; Alarcón-Aris D; Rodríguez-Aller R; Torres-López M; Paz V; Ruiz-Bronchal E; Campa L; Artigas F; Montefeltro A; Revilla R; Bortolozzi A Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33805843 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]